Bülow Pedersen Inge, Laurberg Peter, Knudsen Nils, Jørgensen Torben, Perrild Hans, Ovesen Lars, Rasmussen Lone Banke
Department of Endocrinology and Medicine, Aalborg Hospital, Aarhus University Hospital, Denmark.
Clin Endocrinol (Oxf). 2005 Jun;62(6):713-20. doi: 10.1111/j.1365-2265.2005.02284.x.
Patients with autoimmune overt hypothyroidism may present with goitrous Hashimoto's disease or autoimmune atrophic thyroiditis. Little is known about the prevalence of subclinical autoimmune hypothyroidism. The aims of this study were to evaluate the association between thyroid autoantibodies in serum and abnormalities in thyroid function and structure, and to study the thyroid volume in subjects with subclinical autoimmune hypothyroidism.
A population study including 4649 randomly selected subjects.
Blood tests were used to analyse for thyroid peroxidase autoantibodies (TPO-Ab), thyroglobulin autoantibodies (Tg-Ab), TSH, fT3 and fT4.
Thyroid volume was categorized as small (< 6.6 ml) in 4.7%, normal (6.6-14.9 ml) in 60.4% and large (> 14.9 ml) in 34.9% of participants. Thyroid nodules were found in 29.7%. Serum TSH was low (< 0.4 mIU/l) in 4.7%, normal (0.4-3.6) in 91.0% and high (> 3.6) in 4.3%. The prevalence rate of subclinical goitrous Hashimoto's disease was 0.62% and of subclinical autoimmune atrophic thyroiditis 0.24%. There was a strong association between large volume and autoantibodies, but only in subjects with elevated TSH (P < 0.001). An association between thyroid nodules and TPO-Ab in univariate analyses (P < 0.001) was due to confounding by sex and age (multivariate model, P = 0.23).
We identified a subgroup of the population with subclinical goitrous Hashimoto's disease and a smaller subgroup with subclinical autoimmune atrophic thyroiditis. This relationship between small and large thyroid volume in subclinical disease is opposite to that in overt disease, which may suggest that the period between development of a small volume with circulating autoantibodies and overt hypothyroidism is relatively short.
自身免疫性显性甲状腺功能减退患者可能表现为桥本甲状腺炎伴甲状腺肿大或自身免疫性萎缩性甲状腺炎。关于亚临床自身免疫性甲状腺功能减退的患病率知之甚少。本研究的目的是评估血清甲状腺自身抗体与甲状腺功能及结构异常之间的关联,并研究亚临床自身免疫性甲状腺功能减退患者的甲状腺体积。
一项对4649名随机选取受试者的人群研究。
采用血液检测分析甲状腺过氧化物酶自身抗体(TPO-Ab)、甲状腺球蛋白自身抗体(Tg-Ab)、促甲状腺激素(TSH)、游离三碘甲腺原氨酸(fT3)和游离甲状腺素(fT4)。
4.7%的参与者甲状腺体积被分类为小(<6.6毫升),60.4%为正常(6.6 - 14.9毫升),34.9%为大(>14.9毫升)。发现29.7%的人有甲状腺结节。4.7%的人血清TSH低(<0.4 mIU/l),91.0%正常(0.4 - 3.6),4.3%高(>3.6)。亚临床桥本甲状腺炎伴甲状腺肿大的患病率为0.62%,亚临床自身免疫性萎缩性甲状腺炎为0.24%。甲状腺体积大与自身抗体之间存在强关联,但仅在TSH升高的受试者中存在(P < 0.001)。单因素分析中甲状腺结节与TPO-Ab之间的关联(P < 0.001)是由于性别和年龄的混杂因素所致(多变量模型,P = 0.23)。
我们识别出了亚临床桥本甲状腺炎伴甲状腺肿大的人群亚组以及亚临床自身免疫性萎缩性甲状腺炎的较小亚组。亚临床疾病中甲状腺体积小与大的这种关系与显性疾病相反,这可能表明甲状腺体积小且伴有循环自身抗体到显性甲状腺功能减退的发展期相对较短。